PMID- 31427975
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - Gomisin M2 Inhibits Mast Cell-Mediated Allergic Inflammation via Attenuation of 
      FcepsilonRI-Mediated Lyn and Fyn Activation and Intracellular Calcium Levels.
PG  - 869
LID - 10.3389/fphar.2019.00869 [doi]
LID - 869
AB  - Mast cells are effector cells that induce allergic inflammation by secreting 
      inflammatory mediators. Gomisin M2 (G.M2) is a lignan isolated from Schisandra 
      chinensis (Turcz). Baill. exhibiting anti-cancer activities. We aimed to 
      investigate the anti-allergic effects and the underlying mechanism of G.M2 in 
      mast cell-mediated allergic inflammation. For the in vitro study, we used mouse 
      bone marrow-derived mast cells, RBL-2H3, and rat peritoneal mast cells. G.M2 
      inhibited mast cell degranulation upon immunoglobulin E (IgE) stimulation by 
      suppressing the intracellular calcium. In addition, G.M2 inhibited the secretion 
      of pro-inflammatory cytokines. These inhibitory effects were dependent on the 
      suppression of FcepsilonRI-mediated activation of signaling molecules. To confirm the 
      anti-allergic effects of G.M2 in vivo, IgE-mediated passive cutaneous anaphylaxis 
      (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models were 
      utilized. Oral administration of G.M2 suppressed the PCA reactions in a 
      dose-dependent manner. In addition, G.M2 reduced the ASA reactions, including 
      hypothermia, histamine, interleukin-4, and IgE production. In conclusion, G.M2 
      exhibits anti-allergic effects through suppression of the Lyn and Fyn pathways in 
      mast cells. According to these findings, we suggest that G.M2 has potential as a 
      therapeutic agent for the treatment of allergic inflammatory diseases via 
      suppression of mast cell activation.
FAU - Dhakal, Hima
AU  - Dhakal H
AD  - Cell & Matrix Research Institute, School of Medicine, Kyungpook National 
      University, Daegu, South Korea.
AD  - Department of Pharmacology, School of Medicine, Kyungpook National University, 
      Daegu, South Korea.
FAU - Lee, Soyoung
AU  - Lee S
AD  - Immunoregulatory Materials Research Center, Korea Research Institute of 
      Bioscience and Biotechnology, Jeongeup, South Korea.
FAU - Kim, Eun-Nam
AU  - Kim EN
AD  - College of Pharmacy, Keimyung University, Daegu, South Korea.
FAU - Choi, Jin Kyeong
AU  - Choi JK
AD  - Molecular Immunology Section, Laboratory of Immunology, National Eye Institute, 
      National Institutes of Health, Bethesda, MD, United States.
FAU - Kim, Min-Jong
AU  - Kim MJ
AD  - Department of Pharmacology, School of Medicine, Kyungpook National University, 
      Daegu, South Korea.
FAU - Kang, Jinjoo
AU  - Kang J
AD  - Department of Pharmacology, School of Medicine, Kyungpook National University, 
      Daegu, South Korea.
FAU - Choi, Young-Ae
AU  - Choi YA
AD  - Department of Pharmacology, School of Medicine, Kyungpook National University, 
      Daegu, South Korea.
FAU - Baek, Moon-Chang
AU  - Baek MC
AD  - Department of Molecular Medicine, School of Medicine, Kyungpook National 
      University, Daegu, South Korea.
FAU - Lee, Byungheon
AU  - Lee B
AD  - Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook 
      National University, Daegu, South Korea.
FAU - Lee, Hyun-Shik
AU  - Lee HS
AD  - School of Life Sciences, Kyungpook National University, Daegu, South Korea.
FAU - Shin, Tae-Yong
AU  - Shin TY
AD  - College of Pharmacy, Woosuk University, Jeonju, South Korea.
FAU - Jeong, Gil-Saeng
AU  - Jeong GS
AD  - College of Pharmacy, Keimyung University, Daegu, South Korea.
FAU - Kim, Sang-Hyun
AU  - Kim SH
AD  - Cell & Matrix Research Institute, School of Medicine, Kyungpook National 
      University, Daegu, South Korea.
AD  - Department of Pharmacology, School of Medicine, Kyungpook National University, 
      Daegu, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20190802
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6688163
OTO - NOTNLM
OT  - Gomisin M2
OT  - allergic inflammation
OT  - anaphylaxis
OT  - calcium
OT  - mast cells
EDAT- 2019/08/21 06:00
MHDA- 2019/08/21 06:01
PMCR- 2019/08/02
CRDT- 2019/08/21 06:00
PHST- 2019/03/24 00:00 [received]
PHST- 2019/07/08 00:00 [accepted]
PHST- 2019/08/21 06:00 [entrez]
PHST- 2019/08/21 06:00 [pubmed]
PHST- 2019/08/21 06:01 [medline]
PHST- 2019/08/02 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00869 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Aug 2;10:869. doi: 10.3389/fphar.2019.00869. eCollection 
      2019.